In the context of EGFR-mutant NSCLC, RET fusions have been shown to activate downstream signaling via mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways, bypassing EGFR inhibition and contributing to therapeutic failure (11, 12). The gene discussed is RET; the disease is non-small cell lung carcinoma.